- GSK partner Hansoh reports another phase 3 win for priority ADCHansoh Pharmaceutical has guided its GSK-partnered, B7-H3-directed antibody-drug conjugate to another phase 3 win in China.
- Yarrow to begin trading as it targets Graves; FDA approves Otsuka's ADHD pillPlus news about Outlook Therapeutics, Gossamer Bio, Apnimed and Entera Bio. 📈 Yarrow closes merger to go public: Yarrow Bioscience is developing an anti-TSHR antibody for Graves’ disease and thyro…